AR070346A1 - Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos - Google Patents

Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos

Info

Publication number
AR070346A1
AR070346A1 ARP090100415A ARP090100415A AR070346A1 AR 070346 A1 AR070346 A1 AR 070346A1 AR P090100415 A ARP090100415 A AR P090100415A AR P090100415 A ARP090100415 A AR P090100415A AR 070346 A1 AR070346 A1 AR 070346A1
Authority
AR
Argentina
Prior art keywords
tslpr
inflammatory
lymphopyetine
timica
stromal
Prior art date
Application number
ARP090100415A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR070346A1 publication Critical patent/AR070346A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Reivindicacion 1: Un compuesto de union que se une específicamente al TSLPR de humano y de cyno, que comprende: al menos una region variable de cadena pesada de anticuerpo, o un fragmento de union al TSLPR del mismo, comprendiendo dicha region variable de cadena pesada al menos una secuencia de la CDR seleccionada del grupo integrado por los NOs ID SEC: 1, 2, 3, 73, 7, 8, 9, 13, 14, 15, 19, 20, 21, 25, 26, 27, 31, 32, 33, 37, 38, 39, 43, 44 y 45, o una variante de cualquiera de dichas secuencias; o al menos una region variable de cadena liviana de anticuerpo, o un fragmento de union al TSLPR del mismo, comprendiendo dicha region variable de cadena liviana al menos una secuencia de la CDR seleccionada del grupo integrado por los NOs ID SEC: 4, 5, 6, 74, 10, 11, 12, 16, 17, 18, 22, 23, 24, 28, 29, 30, 34, 35, 36, 40, 41, 42, 46, 47 y 48, o una variante de cualquiera de dichas secuencias.
ARP090100415A 2008-02-07 2009-02-06 Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos AR070346A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2683308P 2008-02-07 2008-02-07
US4203008P 2008-04-03 2008-04-03

Publications (1)

Publication Number Publication Date
AR070346A1 true AR070346A1 (es) 2010-03-31

Family

ID=40622088

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100415A AR070346A1 (es) 2008-02-07 2009-02-06 Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos

Country Status (8)

Country Link
US (1) US8475793B2 (es)
EP (1) EP2250199B1 (es)
JP (2) JP2011511638A (es)
CN (1) CN101986784A (es)
AR (1) AR070346A1 (es)
CA (1) CA2713935C (es)
MX (1) MX2010008688A (es)
WO (1) WO2009100324A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
MX2010013020A (es) * 2008-05-27 2011-03-21 Intra Cellular Therapies Inc Metodos y composiciones para trastornos del sueño y otros trastornos.
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
MY177098A (en) * 2013-08-09 2020-09-05 Astellas Pharma Inc Novel anti-human tslp receptor antibody
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
MX2016007219A (es) 2013-12-03 2016-09-16 Intra-Cellular Therapies Inc Metodos novedosos.
RU2701346C1 (ru) * 2013-12-06 2019-09-25 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
LT3347377T (lt) 2015-09-09 2021-05-25 Novartis Ag Užkrūčio liaukos stromos limfopoetiną (tslp) rišantys antikūnai ir antikūnų panaudojimo būdai
SG11201805123XA (en) 2015-12-18 2018-07-30 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
CN113786407A (zh) 2016-01-26 2021-12-14 细胞内治疗公司 有机化合物
WO2017146011A1 (ja) * 2016-02-22 2017-08-31 国立大学法人 千葉大学 アレルギー性鼻炎の診断用バイオマーカー
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
MX2021013640A (es) 2017-03-24 2022-08-31 Intra Cellular Therapies Inc Composiciones novedosas y metodos.
MX2020007033A (es) * 2018-01-05 2021-02-26 Immunext Inc Anticuerpos anti-mct1 y usos de estos.
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技(成都)有限公司 一种tslp相关病症治疗剂的开发和应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
WO2023155132A1 (zh) * 2022-02-18 2023-08-24 绍兴守仁医疗健康科技有限公司 Rac1蛋白单克隆抗体及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2077279E (pt) * 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
CA2577631A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
AU2007230868B2 (en) 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
KR20100034015A (ko) * 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물

Also Published As

Publication number Publication date
WO2009100324A1 (en) 2009-08-13
CN101986784A (zh) 2011-03-16
CA2713935C (en) 2016-11-01
CA2713935A1 (en) 2009-08-13
JP2013223516A (ja) 2013-10-31
JP2011511638A (ja) 2011-04-14
US20110020369A1 (en) 2011-01-27
MX2010008688A (es) 2010-08-30
EP2250199B1 (en) 2015-09-02
EP2250199A1 (en) 2010-11-17
US8475793B2 (en) 2013-07-02

Similar Documents

Publication Publication Date Title
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
EA201070596A1 (ru) Гуманизированные антитела против tl1a
AR065496A1 (es) Anticuerpos anti- il-23 r
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
EA200802168A1 (ru) Гуманизированное антитело к с-kit
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201070585A1 (ru) Композиции, содержащие антитела к vegf, и способы
ECSP099656A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR082163A1 (es) Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9

Legal Events

Date Code Title Description
FA Abandonment or withdrawal